JPS6416799A - H-pth (1-34) composition and its preparation - Google Patents

H-pth (1-34) composition and its preparation

Info

Publication number
JPS6416799A
JPS6416799A JP62173549A JP17354987A JPS6416799A JP S6416799 A JPS6416799 A JP S6416799A JP 62173549 A JP62173549 A JP 62173549A JP 17354987 A JP17354987 A JP 17354987A JP S6416799 A JPS6416799 A JP S6416799A
Authority
JP
Japan
Prior art keywords
organic acid
peptide
pth
salt
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP62173549A
Other languages
Japanese (ja)
Other versions
JP2505812B2 (en
Inventor
Ko Morita
Toshiharu Noda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyo Jozo KK
Original Assignee
Toyo Jozo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Jozo KK filed Critical Toyo Jozo KK
Priority to JP62173549A priority Critical patent/JP2505812B2/en
Publication of JPS6416799A publication Critical patent/JPS6416799A/en
Application granted granted Critical
Publication of JP2505812B2 publication Critical patent/JP2505812B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PURPOSE:To obtain the title stabilized composition of increased thermal stability, by evaporating off the organic acid from the salt of human parathyroid hormone peptide (1-34) with a volatile organic acid as much as possible, then freeze-drying an aqueous solution of the hormone peptide in a tartaric acid aqueous solution of a specific concentration. CONSTITUTION:A volatile organic acid salt of human parathyroid hormone (h-PTH) peptide (1-34) of the formula is synthesized by the solid phase method and purified by chromatography or the like. Then, the volatile organic acid is removed from the salt as much as possible and the remaining peptide is dissolved in such a tartaric acid aqueous solution as the amount of tartaric acid ranges from 1.8 to 25wt.% based on the total amount and the solution is freeze-dried to give the subject stabilized h-PTH (1-34) composition.
JP62173549A 1987-07-10 1987-07-10 Freeze-dried composition of h-PTH (1-34) Expired - Lifetime JP2505812B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62173549A JP2505812B2 (en) 1987-07-10 1987-07-10 Freeze-dried composition of h-PTH (1-34)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62173549A JP2505812B2 (en) 1987-07-10 1987-07-10 Freeze-dried composition of h-PTH (1-34)

Publications (2)

Publication Number Publication Date
JPS6416799A true JPS6416799A (en) 1989-01-20
JP2505812B2 JP2505812B2 (en) 1996-06-12

Family

ID=15962594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62173549A Expired - Lifetime JP2505812B2 (en) 1987-07-10 1987-07-10 Freeze-dried composition of h-PTH (1-34)

Country Status (1)

Country Link
JP (1) JP2505812B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029337A1 (en) * 1997-12-09 1999-06-17 Eli Lilly And Company Stabilized teriparatide solutions
WO2002002136A1 (en) * 2000-06-30 2002-01-10 Suntory Limited Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP1623723A3 (en) * 1998-05-22 2006-05-10 Dainippon Sumitomo Pharma Co., Ltd. Stable gene formulations
WO2011030774A1 (en) 2009-09-09 2011-03-17 旭化成ファーマ株式会社 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
WO2011062073A1 (en) 2009-11-18 2011-05-26 旭化成ファーマ株式会社 Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis
WO2012169435A1 (en) 2011-06-07 2012-12-13 旭化成ファーマ株式会社 Freeze-dried preparation containing high-purity pth and method for producing same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303100C (en) * 2005-04-28 2007-03-07 华东理工大学 Method for preliminary purification of recombinant human parathormone fusion protein by thermo osmosis shock technology

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550434B2 (en) 1997-12-09 2009-06-23 Eli Lilly And Company Stabilized teriparatide solutions
EP0920873A3 (en) * 1997-12-09 1999-08-04 Eli Lilly And Company Stabilized teriparatide solutions
WO1999029337A1 (en) * 1997-12-09 1999-06-17 Eli Lilly And Company Stabilized teriparatide solutions
EP1417972A1 (en) * 1997-12-09 2004-05-12 Eli Lilly & Company Stabilized teriparatide solutions
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP1623723A3 (en) * 1998-05-22 2006-05-10 Dainippon Sumitomo Pharma Co., Ltd. Stable gene formulations
US7087248B2 (en) 2000-06-30 2006-08-08 Daiichi Asubio Pharma Co., Ltd. Pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration comprising the component
WO2002002136A1 (en) * 2000-06-30 2002-01-10 Suntory Limited Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
EP2682125A1 (en) 2009-09-09 2014-01-08 Asahi Kasei Pharma Corporation Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 200 units
WO2011030774A1 (en) 2009-09-09 2011-03-17 旭化成ファーマ株式会社 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
KR20210040171A (en) 2009-09-09 2021-04-12 아사히 가세이 파마 가부시키가이샤 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week in a unit dose of 100 to 200 units
KR20190095552A (en) 2009-09-09 2019-08-14 아사히 가세이 파마 가부시키가이샤 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week in a unit dose of 100 to 200 units
EP2682124A1 (en) 2009-09-09 2014-01-08 Asahi Kasei Pharma Corporation Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
KR20120116901A (en) 2009-11-18 2012-10-23 아사히 가세이 파마 가부시키가이샤 Preventive and/or therapeutic and/or aggravation suppressing agent for human arthritis deformans
WO2011062073A1 (en) 2009-11-18 2011-05-26 旭化成ファーマ株式会社 Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis
EP3020409A1 (en) 2011-06-07 2016-05-18 Asahi Kasei Pharma Corporation Freeze-dried preparation containing high-purity pth and method for producing same
KR20160068987A (en) 2011-06-07 2016-06-15 아사히 가세이 파마 가부시키가이샤 Freeze-dried preparation containing high-purity pth and method for producing same
EP3170493A1 (en) 2011-06-07 2017-05-24 Asahi Kasei Pharma Corporation Freeze-dried preparation containing high-purity pth and method for producing same
US10011643B2 (en) 2011-06-07 2018-07-03 Asahi Kasei Pharma Corporation Freeze-dried preparation containing high-purity PTH and method for producing same
WO2012169435A1 (en) 2011-06-07 2012-12-13 旭化成ファーマ株式会社 Freeze-dried preparation containing high-purity pth and method for producing same

Also Published As

Publication number Publication date
JP2505812B2 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
PT78711B (en) NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF
RU94028887A (en) MIXTURE OF HIGHER PRIMARY ALIPHATIC ALCOHOLS, METHOD FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION BASED ON
EP0215658A3 (en) Improved formulation for recombinant beta-interferon processes for recovery and stabilization of beta-interferon and the use thereof
DK262683A (en) DYNORPHINAMIDE ANALOGS
FI910286A0 (en) ANALOGER AV HUMANT INSULIN OCH PREPARAT INNEHAOLLANDE DESSA.
JPS54147916A (en) Preparation of urokinase injection
JPS559023A (en) Production of dopa preparation in high concentration
SG46307A1 (en) New pyrazine derivatives the preparation and use thereof
JPS6416799A (en) H-pth (1-34) composition and its preparation
IT1241153B (en) METHOD FOR PREPARING STABLE BITUMEN-POLYMER MIXTURES
DE3773017D1 (en) PREPARATION FOR INJECTION CONTAINING NICORANDIL.
DE3676640D1 (en) PRAZOSINE-PIRBUTEROL MIXTURE FOR BRONCH DILATATION.
DE69217686T2 (en) Pharmaceutical composition of stabilized [Leu 13] motilin pod
JPS51125790A (en) Carrier for fixing of biologically active substances
HU911358D0 (en) Grf analogues
JPS5289684A (en) Preparation of triesters of isocyanuric acid
JPS5533446A (en) Amino acid transfusion for postoperative patient
JPS5283411A (en) Preparation of 3,3-dimethyl-4-pentenoic acid and its derivatives
JPS53112815A (en) Preparation of derivative of aliphatic isothiocyanic acid having basic substituent
JPS53113033A (en) Antihyperlipemics
JPS5498306A (en) Preparation of human blood-plasma cholinesterase
JPS6437823A (en) Electrolyte for driving electrolytic capacitor
JPS57189662A (en) Improvement of sweeteness of thaumatin
JPS5365867A (en) Preparation of chenodeoxycholic acid crystal
JPS5625114A (en) Preparation of human gamma globulin